National Heart and Lung Institute, Imperial College London, London, UK.
Host Defence Unit, Dept of Respiratory Medicine, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Eur Respir Rev. 2022 Feb 9;31(163). doi: 10.1183/16000617.0212-2021. Print 2022 Mar 31.
Nontuberculous mycobacterial pulmonary disease (NTM-PD) remains a challenging condition to diagnose and treat effectively. Treatment of NTM-PD is prolonged, frequently associated with adverse effects and has variable success. In this review, we consider the factors influencing clinicians when treating NTM-PD and discuss outcomes from key studies on the pharmacological management of complex pulmonary disease and pulmonary disease. We highlight issues relating to treatment-related toxicity and provide an overview of repurposed and emerging therapies for NTM-PD.
非结核分枝杆菌肺病（NTM-PD）仍然是一种具有挑战性的疾病，难以有效诊断和治疗。NTM-PD 的治疗时间长，常伴有不良反应，且疗效不一。在这篇综述中，我们考虑了影响临床医生治疗 NTM-PD 的因素，并讨论了关于复杂肺部疾病和肺部疾病药物治疗的关键研究的结果。我们强调了与治疗相关毒性有关的问题，并对 NTM-PD 的重新利用和新兴治疗方法进行了概述。
